CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2023	Aug. 31, 2022	Aug. 31, 2021
Cash flows from operating activities
Net income	$ 9,961	$ 12,483	$ 9,782
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	3,840	3,574	3,590
Change in fair value of contingent consideration	680	283	486
Amortization of investment (discounts) premiums	(1,134)	1,678	2,350
Stock-based compensation	4,828	3,037	2,750
Deferred income taxes	(2,095)	(270)	(628)
Loss (gain) from disposal of assets	6	0	0
Impairment of other intangibles	500	0	0
Currency translation adjustments	167	(265)	(101)
Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]
Accounts receivable	4,097	(3,936)	(2,429)
Prepaid income taxes	587	(379)	(42)
Prepaid expenses and other assets	(501)	1,081	(157)
Accounts payable	(81)	(162)	39
Other liabilities	832	(1,437)	3,353
Accrued income taxes	(7)	0	0
Deferred revenue	176	2,213	210
Net cash provided by operating activities	21,856	17,900	19,203
Cash flows from investing activities
Purchases of property and equipment	(453)	(819)	(1,627)
Purchase of short-term investments	(95,045)	(100,846)	(122,395)
Proceeds from maturities of short-term investments	114,907	109,121	100,229
Purchased intangibles	(601)	0	0
Acquisition of Immunetrics, net of cash acquired	(8,223)	0	0
Capitalized computer software development costs	(3,219)	(3,151)	(2,949)
Net cash provided by (used in) investing activities	7,366	4,305	(26,742)
Cash flows from financing activities
Payment of dividends	(4,809)	(4,846)	(4,811)
Payments on contracts payable	0	(3,667)	(1,334)
Proceeds from the exercise of stock options	1,543	891	1,461
Repurchase and retirement of common shares	(20,000)	0	0
Net cash used in financing activities	(23,266)	(7,622)	(4,684)
Net increase (decrease) in cash and cash equivalents	5,956	14,583	(12,223)
Cash and cash equivalents, beginning of year	51,567	36,984	49,207
Cash and cash equivalents, end of period	57,523	51,567	36,984
Supplemental disclosures of cash flow information
Income taxes paid	3,204	3,233	1,857
Non-Cash Investing and Financing Activities
Stock issued for acquisition of Lixoft	0	1,166	666
Creation of contract liabilities from acquisition of subsidiaries	5,900	0	0
Right of use assets capitalized	$ 227	$ 624	$ 905